Implications of early inflammation and infection in cystic fibrosis: A review of new and potential interventions
โ Scribed by Peter H. Weller
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 23 KB
- Volume
- 24
- Category
- Article
- ISSN
- 8755-6863
No coin nor oath required. For personal study only.
โฆ Synopsis
Airway infection and inflammation occur early in cystic fibrosis (CF) lung disease, suggesting the need for early treatment. Our current approach to routine management of CF includes a comprehensive, CF center-directed program that aims at maintaining normal nutrition and delaying the progression of lung disease. Regular secretion clearance, frequent antibiotics, and bronchodilators are commonly used. However, despite this early, aggressive comprehensive management, airway inflammation and infection progress. Several other recent approaches such as the use of corticosteroids and ibuprofen to decrease inflammation, as well as dornase alfa to thin secretions and improve pulmonary function, are under investigation in young children. Other potential treatments include amiloride/uridine triphosphate and hypertonic saline aerosol. Early treatment offers the promise of reducing morbidity as well as delaying the progression of later disease.
๐ SIMILAR VOLUMES
Trials of rhDNase in mixed groups of adults and children with cystic fibrosis (CF) have demonstrated improvements in lung function and well-being. This has led to many pediatric CF patients receiving regular rhDNase therapy although their response to treatment may not be the same as that seen in adu
Cystic fibrosis (CF) is an inherited disorder associated with severe inflammation and repeated bacterial infection and colonization in the lung. Airway epithelium is involved in defence against bacteria, but this system may be defective in CF. Pro-inflammatory cytokines can stimulate the expression
Airway inflammation and infection are present in patients with mild lung disease in cystic fibrosis (CF), suggesting the need for early treatment. In a previously reported large multicenter trial, dornase alfa improved pulmonary function and decreased the need for hospitalization in patients with CF
The mutation described here has been detected in the DNA of a female cystic fibrosis (CF) patient born in May 1963. CF has been diagnosed only at the age of 30 years and has been confirmed by three positive sweat tests. She does not require supplementation with pancreatic enzymes and her pulmonary f